SCHEMBL4291869

SCHEMBL4291869

Brc1ccc2[nH]nc(-c3cccs3)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.60
CLK4 Q9HAZ1 2/20 0.60
DCLK1 O15075 1/20 0.60
PRKD3 O94806 1/20 0.60
MAP4K4 O95819 1/20 0.60
CHEK2 O96017 1/20 0.60
CSF1R P07333 1/20 0.60
FER P16591 1/20 0.60
CDK2 P24941 1/20 0.60
MARK3 P27448 1/20 0.60
FLT4 P35916 1/20 0.60
MAPK9 P45984 1/20 0.60
CSNK1D P48730 1/20 0.60
CLK2 P49760 1/20 0.60
CSNK2A1 P68400 1/20 0.60
CSNK1G2 P78368 1/20 0.60
MAP4K2 Q12851 1/20 0.60
STK3 Q13188 1/20 0.60
CAMK2B Q13554 1/20 0.60
CAMK2G Q13555 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2614376 0.82 CDC7 (0.48) CDK2PDPK1CDC7MEN1KMT2A
SCHEMBL27756320 0.79 KDM4E (0.56) PDPK1CDC7HTR2AHTR2CHTR2B
SCHEMBL4290310 0.76 FLT3 (0.56) FLT3CLK4DCLK1PRKD3MAP4K4
SCHEMBL2731639 0.76 FLT3 (0.75) FLT3CLK4DCLK1PRKD3MAP4K4
SCHEMBL4316858 0.76 DCLK1 (1.00) FLT3CLK4DCLK1PRKD3MAP4K4
SCHEMBL5388514 0.74 CDC7 (0.53) CLK2CSNK2A1DYRK1ACDC7ALDH1A1
SCHEMBL8258330 0.74 CDC7 (0.53) CDK2CLK2DYRK1ACDC7MEN1
SCHEMBL3920232 0.73 CDC7 (0.44) CDC7MEN1KMT2AKDM4EALDH1A1
SCHEMBL28026093 0.72 ITK (0.49) FLT3CDK2AURKBCDC7KDM4E
SCHEMBL3918045 0.72 CDC7 (0.43) CDK2CLK2DYRK1ACDC7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885CLK4 260/4885DCLK1 503/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885CLK4 260/4885DCLK1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.